Golimumab (Simponi®) for UC

Assessment Status Assessment process complete
Drug Golimumab
Brand Simponi®
Indication For the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments.
Assessment Process
Rapid review commissioned 11/10/2013
Rapid review completed 31/10/2013
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended.